Cargo Therapeutics(CRGX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., August 12, 2024 – CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, poten ...